In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Spiderman, but kind of goth: University of Bayreuth team creates red silk-producing spiders
In Germany, researchers at the University of Bayreuth’s Biomaterials research group have used the CRISPR-Cas9 gene-editing technology to create spiders that produce red fluorescent...
BoilMate corn-fiber cooking bowl seeks funding on Kickstarter
In California, Transcarton has launched a Kickstarter campaign for BoilMate—the world’s first fire-safe, compostable paper bowl engineered for instant cooking.
BoilMate combines FDA-approved corn fiber...
Natural Indigo Finland, TAMK turn coffee waste into ink for packaging
In Finland, Natural Indigo Finland and Tampere University of Applied Sciences (TAMK) have developed a water-based ink using biocolorant extracted from coffee waste supplied...